A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biotechnology company developing therapies for neurodegenerative diseases, with a focus on areas of high unmet medical need. Our work is informed by advances in disease biology, including the roles of misfolded or deficient proteins, lysosomal dysfunction, and immune and neuronal pathway disruption. Our objective is to develop product candidates that address disease through targeted mechanisms, such as removing pathogenic proteins, replacing deficient proteins, and restoring normal cellular function. We are advancing a portfolio of programs focused on genetically validated targets, supported by our expertise in drug development, protein engineering, and antibody discovery. A key component of our strategy is the development and application of our Alector Brain Carrier (ABC) platform, a proprietary blood-brain barrier (BBB) delivery technology designed to improve central nervous system exposure across multiple therapeutic modalities.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 101M | 97M | 134M | 207M |
| Net Income | -143M | -143M | -119M | -130M | -133M | -36M |
| EPS | $-1.39 | $-1.39 | $-1.23 | $-1.56 | $-1.62 | $-0.45 |
| Free Cash Flow | -184M | -184M | -231M | -187M | -24M | 295M |
| ROIC | -42.0% | -42.0% | -87.4% | -97.2% | -62.2% | -12.1% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.32 | 0.32 | 0.07 | 0.00 | 2.67 | 1.71 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -156M | -156M | -145M | -152M | -138M | -37M |
| Operating Margin | 0.0% | - | -144.2% | -156.3% | -103.2% | -18.0% |
| ROE | -466.3% | -181.6% | -93.9% | -97.2% | -62.2% | -12.1% |
| Shares Outstanding | 103M | 103M | 97M | 84M | 82M | 81M |
Alector, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is +3.1%.
Alector, Inc. (ALEC) has a 5-year average return on invested capital (ROIC) of -60.2%. This is below average and may indicate limited pricing power.
Alector, Inc. (ALEC) has a market capitalization of $248M. It is classified as a small-cap stock.
Alector, Inc. (ALEC) does not currently pay a regular dividend.
Alector, Inc. (ALEC) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Alector, Inc. (ALEC) generated $-184 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Alector, Inc. (ALEC) has a debt-to-equity ratio of 0.32. This indicates a conservatively financed balance sheet.
Alector, Inc. (ALEC) reported earnings per share (EPS) of $-1.39 in its most recent fiscal year.
Alector, Inc. (ALEC) has a return on equity (ROE) of -181.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 9 years of financial data for Alector, Inc. (ALEC), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Alector, Inc. (ALEC) has a book value per share of $0.30, based on its most recent annual SEC filing.